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The Rap1 gene was discovered in a tis-
sue culture-based genetic screen as a
suppressor of Ras transformation in
rodent fibroblasts (Kitayama et al.,
1989). Indeed Rap1, when expressed at
high levels, can compete with Ras sig-
naling by binding to but not activating
Ras effector molecules, such as c-Raf
(Cook et al., 1993). However, more phys-
iologically relevant activation of endoge-
nous Rap1, by growth factors, does not
seem to repress Ras-mediated activa-
tion of ERK (Zwartkruis et al., 1998).
Moreover, expression of Rap1 at high
levels can morphologically transform
Swiss 3T3 fibroblasts, causing increased
saturation density and decreased dou-
bling time (Altschuler and Ribeiro-Neto,
1998). Finally, in certain cell lines, Rap1
is capable of activating ERK via activa-
tion of B-raf (York et al., 1998). Since
these early discoveries, many scientists,
after years of work, have not yet deter-
mined whether Rap1 normally antago-
nizes Ras signaling or can be a “bad
actor” in cancer, delivering an oncogenic
signal, just as Ras does. Indeed, Rap1
may do both things. The paper by Ishida
et al. in this issue of Cancer Cell provides
evidence suggesting that Rap1 can
deliver an oncogenic signal in vivo, may
do so in collaboration with RAS/ERK sig-
naling, and is especially important for
maintaining normal myelopoiesis.
The authors present data on the
effects of targeted disruption of a Rap1-
specific GTPase-activating protein
(GAP) gene called SPA-1 in mice. At
about one year of age, SPA-1−/− mice
develop one of three related disorders
resembling human chronic myeloprolifer-
ative or myelodysplastic diseases. Some
of the mice developed myelodysplastic
disease with pancytopenia and abnor-
mal granulocytes and megakaryocytes
present in circulation. Another group had
peripheral leukocytosis with circulation
of immature blast-like cells of various lin-
eages. In at least some of these mice,
mono or oligoclonality of B lineage blast
cells could be documented. A third group
developed a chronic myeloproliferative
disease. SPA-1−/− preleukemic lineage-
negative bone marrow cells showed
increased Rap1 and ERK activation with-
out any change in Ras activation.
However, the blast crisis disease that
develops in SPA-1−/− mice was associat-
ed with increased basal Rap1 and
RasGTP levels. These data suggest that
Ras activation might cooperate with
Rap1 activation in disease progression
in this setting. Nevertheless, Rap1 acti-
vation seems to be critical for mainte-
nance of the transformed state, since
transduction of the SPA-1 gene into a
SPA-1−/− myeloid leukemia cell line inhib-
ited Rap1 activation and leukemogenici-
ty in SCID mice without affecting
RasGTP or activated ERK levels.
Furthermore, transduction of normal
marrow cells with an activated form of
Rap1 resulted in enhanced proliferation
in vivo. The spectrum of hematologic dis-
ease seen in SPA-1−/− mice is remarkable
and suggests that Rap1GTP plays a vital
role in controlling normal hematopoiesis.
These data also help to explain the find-
ing that a Rap1-specific guanine
nucleotide exchange factor, called
RasGRP2 or CAL-DAG-GEF I, is activat-
ed by proviral insertion in a subset of
BXH-2 strain acute myeloid leukemias
(Dupuy et al., 2001). Taken together,
these data suggest that Rap1 activation
may be a general feature of myelodys-
plasia, myeloid leukemia, and possibly
other human cancers.
Does Rap1 signaling play a role in
human myeloid leukemia and contribute
to cancer in other settings? Certainly the
data provided by Ishida and colleagues
(2003) demonstrate that SPA-1 might be
a myeloid tumor suppressor gene, and
so changes in SPA-1 gene expression in
primary leukemic cells should be sought.
The SPA-1 gene maps to human chro-
mosome 11q13, a site frequently altered
in human leukemia (Mitelman et al.,
1997). Other suggestive evidence for a
role of Rap1 in cancer comes from study
of oncogenic human papillomaviruses
(HPV). A cellular Rap1GAP, called
E6TP1, is targeted for ubiquitin-mediat-
ed degradation by the viral E6 oncopro-
tein, suggesting that resultant hyperacti-
vation of Rap1 might contribute to
cervical and other cancers associated
with chronic HPV infection (Singh et al.,
2003). Another bit of suggestive evi-
dence comes from the study of a human
tumor predisposition syndrome called
tuberous sclerosis type 2 (TSC-2).
Inherited as an autosomal, dominant dis-
ease, somatic inactivation of TSC2 pre-
disposes to  benign and rarely malignant
tumors. Tuberin, the product of the TSC2
gene, encodes a Rap1GAP (Wienecke
et al., 1995). Interestingly, sporadic
glioma often shows loss of tuberin
expression or increased Rap1 expres-
sion (Gutmann et al., 1997).
How does Rap1 signaling contribute
to cancer? Two likely scenarios are acti-
vation of a B-Raf/MEK/ERK signaling
pathway or integrin activation. Cell bio-
logical and genetic studies suggest that
Rap1 is involved in delivering a signal
leading to integrin activation and
increased cell adhesion (Arai et al.,
2001). This could in turn lead to
increased “outside-in” signaling mediat-
ed by engagement of integrins by their
ligands. The net effect may be that
hematopoietic cells more easily survive
outside of their normally occupied niches
in the bone marrow. In time, this could
lead to the effects observed in the SPA-
1−/− mice. Presumably, additional envi-
ronmental or genetic events provide
signals required for more aggressive dis-
ease. In particular, Ishida et al. observed
high levels of Ras activation in the blast
crisis leukemia that developed in some
mice. These data suggest that leukemo-
genesis may be associated with the
coordinate dysregulation of multiple Ras
superfamily members, which provides
the correct balance of phenotypic effects
to maintain the leukemic cell phenotype.
Either Rap1 or Ras activation may occur
during the preleukemic period, requiring
different subsequent events for disease
progression. Other Ras superfamily
members that seem to play a role in can-
cer include Rac, Cdc42, and Rho pro-
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A bad rap: Rap1 signaling and oncogenesis
In the paper by Ishida et al. in this issue of Cancer Cell, the authors report the results of targeted inactivation of a Rap1-spe-
cific GTPase-activating protein (GAP) gene, called SPA-1, in mice. Rap1 hyperactivation was observed in hematopoietic
cells, which led over time to features associated with symptoms typical of human myeloid dyslastic and myeloid prolifera-
tive diseases. The authors present additional data showing that the level of Rap1 activation is important for regulating
myelopoiesis and that, in the right context, can deliver an oncogenic signal.
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teins, each of which have been implicat-
ed in Ras transformation of fibroblasts.
Although SPA-1 seems to be the pre-
dominant Rap1GAP in blood cell precur-
sors, it remains possible that additional
or other roles of the SPA-1 protein are
involved in the in vivo effects observed
by Ishida and colleagues. However, it
seems likely that Rap1 is central to the
effects of SPA-1 deletion since an acti-
vated Rap1 gene, when overexpressed
via retroviral transduction in primary
bone marrow cells, causes a hyper-
myeloid phenotype. These studies need
to be followed up with more phenotypic
analyses, however. An additional unre-
solved question is the role that other
Rap1GAPs might have in suppressing
tumor cell growth in other tissues. As
originally proposed by Altschuler and
Ribeiro-Neto (1998), it seems plausible
that only certain cell types are sensitive
to transformation by Rap1 signaling. Also
mysterious are the mechanisms that reg-
ulate Rap1’s ability to suppress RasGTP
activity in some contexts and deliver sig-
nals that promote growth in others.
Recent data suggest that the subcellular
localization of Rap1GAP activity deter-
mines whether RasGTP signaling is sup-
pressed by Rap1, and that the two
GTPases are normally activated in differ-
ent subcellular regions of the cell (Ohba
et al., 2003). Therefore, in some cell
types and in response to the certain
stimuli, Rap1 may suppress RasGTP
signaling and proliferation. The rules
governing the phenotypic effects of Rap1
signaling remain obscure. Some of the
answers will be found when more of
Rap1’s downstream effectors and
upstream regulators are identified, and
their biological roles can be revealed in
genetic experiments like those present-
ed by Ishida and colleagues in this issue
of Cancer Cell.
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A generally accepted model for tumor
progression through clonal evolution is
illustrated in the left portion of Figure 1.
Evolutionary details are particularly well
worked out in colorectal cancer (Fearon
and Vogelstein, 1990). One important
prediction of the clonal progression
model is that the spectrum of aberrations
in metastatic lesions will be similar to
those in the primary tumors from which
they originated since the metastases
represent the end stage of evolution.
Karyotypic and genomic analyses of
cancers of the breast (Kuukasjarvi et al.,
1997; Pandis et al., 1998), bladder
(Hovey et al., 1998), colon (Al-Mulla et
al., 1999), and kidney (Bissig et al.,
1999) often show this feature. However,
these studies also show exceptions
where some metastases bear almost no
genomic resemblance to the primary
tumor from the same patient. Bessig et
al., for example, found that ?30% of
renal cell metastases were almost com-
pletely different from the primary tumors
in the same patients. Likewise,
Kuukasjärvi et al. (1997) found a signifi-
cant fraction of breast metastases that
were not strongly clonally related to the
primary tumors in the same patients.
They also analyzed metastases at sever-
al sites in individual patients and found
substantial evolutionary divergence
between these metastatic lesions and
the primary tumor AND between the
metastases themselves. In most cases,
Evidence emerges for early metastasis and parallel evolution of
primary and metastatic tumors
Tumor progression to metastasis usually is assumed to occur through clonal genomic and epigenetic evolution. However,
Schmidt-Kittler et al. (2003) present evidence that challenges this paradigm.They show that genomic aberrations in tumor
cells disseminated in the bone marrows of patients with no clinical evidence of metastasis generally do not resemble the
aberrations in the primary tumors from which they arose. They interpret this to mean that tumor cells disseminate very
early and evolve to metastatic disease independent from the primary tumor.Their model suggests that adjuvant therapies
should be targeted to lesions in the disseminated cells rather than lesions found in primary tumors.
